| Nov 14 |
Benitec GAAP EPS of -$0.48
|
| Nov 14 |
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
|
| Nov 4 |
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
|
| Oct 17 |
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
|
| Oct 16 |
Benitec started at outperform by Oppenheimer on gene therapy potential
|
| Oct 14 |
Benitec Biopharma Announces Updated Investor Webcast Information
|
| Oct 12 |
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
|
| Oct 9 |
Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages
|
| Oct 1 |
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc
|
| Sep 28 |
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
|
